Karolinska Development AB: Pergamum Reports Positive Follow-Up Data From a Phase II Clinical Trial of PXL-01 for Prevention of Post-Surgical Adhesions

Published: Jun 27, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Pergamum AB announced today that several end-points were met in a randomized Phase II trial of PXL-01 for prevention of post-surgical adhesions. Karolinska Development AB is the majority owner of Pergamum. Many patients undergoing hand surgery suffer from debilitating scar formation, which reduces the range of motion and complicates daily activities. PXL-01 is a novel therapeutic peptide that has been developed with the purpose to reduce the formation of obstructing scars and restore mobility and function.

Help employers find you! Check out all the jobs and post your resume.

Back to news